Instrument Inactif

Communiqués Raptor Pharmaceutical Corp

Actions

US75382F1066

Recherche biotechnologique et médicale

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

16/09/16	Depomed : Le laboratoire Depomed résigné à se vendre-sources	RE
14/09/15	Apple : Les valeurs à suivre sur les marchés aùéricains	RE

Communiqués

21/09/16	SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of Raptor Pharmaceutical Corp. -RPTP	PR
19/09/16	RAPTOR PHARMACEUTICAL SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Raptor Pharmaceutical Corp. (RPTP) Over the Proposed Sale of the Company to Horizon Pharma plc	PR
15/09/16	Brower Piven Commences An Investigation Into The Proposed Sale Of Raptor Pharmaceutical Corp. And Encourages Shareholders To Contact The Firm For Additional Information	BU
15/09/16	Levi & Korsinsky, LLP Announces an Investigation Regarding the Fairness of the Sale of Raptor Pharmaceutical Corp. to Horizon Pharma Plc for $9.00 Per Share	BU
14/09/16	Raptor Pharmaceutical : Acquisition May Not Be in the Best Interests of RPTP Shareholders	PR
12/09/16	Brower Piven Commences An Investigation Into The Proposed Sale Of Raptor Pharmaceutical Corp. And Encourages Investors To Contact The Firm For Additional Information	BU
12/09/16	Robbins Arroyo LLP: Acquisition of Raptor Pharmaceutical Corp. (RPTP) by Horizon Pharma plc (HZNP) May Not Be in Shareholders' Best Interests	BU
12/09/16	RAPTOR PHARMACEUTICAL CORP. Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Horizon Pharma plc	BU
12/09/16	RAPTOR PHARMACEUTICAL CORP. Rigrodsky & Long, P.A. Announces Investigation Of Buyout	BU
12/09/16	RAPTOR (RPTP) ALERT: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in Proposed Sale of Raptor Pharmaceutical Corp.; Are Shareholders Getting a Fair Price?	PR
07/09/16	Raptor Pharmaceutical Presents Results from Meta-Analysis Demonstrating Efficacy of QUINSAIR™ Comparable to Other Approved, Inhaled Antibiotics in Cystic Fibrosis Patients	GL
24/08/16	Raptor Pharmaceutical to Present Data on QUINSAIR™ and Other Inhaled Antibiotics at the ERS International Congress	GL
18/08/16	Raptor Pharmaceutical : Voted A "Best Places to Work" Company in the North San Francisco Bay Area	PU
18/08/16	Raptor Pharmaceutical Voted A “Best Places to Work” Company in the North San Francisco Bay Area	GL
16/08/16	Raptor Pharmaceutical : Biotech Stocks Technical Report -- Incyte, BioDelivery Sciences Intl., Synthetic Biologics, and Raptor Pharma	PR
04/08/16	Raptor Pharmaceutical Corp. Reports Second Quarter 2016 Financial Results	GL
28/07/16	Raptor Pharmaceutical to Hold Second Quarter 2016 Financial Results Conference Call and Webcast on Thursday, August 4, 2016, at 4:30 p.m. EDT	GL
14/06/16	Raptor Pharmaceutical to Participate in the 2016 JMP Life Sciences Conference	GL
10/06/16	Raptor Pharmaceutical Announces Presentation of New Data Analyses from a Phase 3 Study of QUINSAIR™ at the 39th European Cystic Fibrosis Conference	GL
07/06/16	Raptor Pharmaceutical : to Present Data on QUINSAIR™ at European Cystic Fibrosis Conference	PU
07/06/16	Raptor Pharmaceutical to Present Data on QUINSAIR™ at European Cystic Fibrosis Conference	GL
05/05/16	Raptor Pharmaceutical Corp. Reports First Quarter 2016 Financial Results	GL
28/04/16	Raptor Pharmaceutical to Hold First Quarter 2016 Financial Results Conference Call and Webcast on Thursday, May 5, 2016, at 4:30 p.m. ET	GL
11/04/16	Raptor Pharmaceutical Launches QUINSAIR™ in Europe	GL
21/03/16	Raptor Pharmaceutical : PROCYSBI® New Drug Submission Accepted by Health Canada with Priority Review	PU